Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using a potassium‑competitive acid blocker after PCI to protect the stomach.

Official title: Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Run by Samsung Medical Center · NCT07068490 · Data updated 2026-11-12

We will see if giving a potassium‑competitive acid blocker instead of a proton pump inhibitor helps prevent stomach bleeding in people who had PCI and are taking dual antiplatelet medicines.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100000 (estimated)
SponsorSamsung Medical Center
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedOctober 22, 2024
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedJuly 16, 2025
Trial IDNCT07068490 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People who underwent PCI, are taking aspirin plus clopidogrel, prasugrel, or ticagrelor, and who have not used a P‑CAB, PPI, or H2 blocker in the past month are eligible.

Probably not a fit

Patients who are already prescribed a PPI because of their bleeding risk or those with high GI bleeding risk who are not taking a PPI (and thus were excluded) are unlikely to benefit from enrollment in this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational target‑trial emulation comparing routine use of potassium‑competitive acid blockers (P‑CABs) versus guideline‑directed proton pump inhibitor (PPI) use for gastrointestinal protection in patients who underwent percutaneous coronary intervention (PCI) and remain on dual antiplatelet therapy (DAPT). The study uses real‑world clinical data from Samsung Medical Center to compare efficacy (GI bleeding prevention) and safety (including cardiovascular events) between the two approaches. Researchers will apply statistical methods to emulate a randomized trial and adjust for confounding factors such as baseline bleeding risk and concomitant medications. Outcomes will include rates of GI bleeding, major adverse cardiovascular events, and other safety endpoints during follow‑up.

Why it matters

Potential benefit: If successful, this approach could offer equal or better stomach protection for PCI patients on DAPT with comparable cardiovascular safety, potentially reducing GI bleeding and related hospital visits.

How similar studies have gone: Previous trials show P‑CABs provide stronger acid suppression than PPIs, but there is limited direct evidence on GI bleeding or cardiovascular outcomes in patients on DAPT, so this clinical application remains relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients who underwent PCI
* Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
* No use of PCAB, PPI, or an H2-receptor within the past month

Exclusion Criteria:

* Patients with low GI bleeding risk are taken on PPI
* Patients with high GI bleeding risk do not take PPI

Where it's running

  • Samsung Medical Center
    Seoul, South Korea
    Recruiting

Study contacts

  • Principal investigator: KI HONG CHOI, MD, PhD — Samsung Medical Center
  • Study coordinator: Ki Hong Choi, MD, PhD
  • Email: cardiokh@gmail.com
  • Phone: 82-2-3410-3419

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.